日本血吸虫重组信号蛋白14-3-3疫苗免疫保护性的观察

目的　研究日本血吸虫(中国大陆株)重组信号蛋白1433(rSj1433)作为血吸虫病疫苗分子的潜能,并探讨rSj1433、rSjGST两种重组蛋白作为疫苗的协同作用及结核杆菌低分子量耐热多肽(Mtb)激活的γδT细胞在抗血吸虫病中的作用。　方法　用SDSPAGE、电洗脱和透析的方法制备rSj1433和rSjGST抗原,将两种抗原(分别用福氏佐剂和Mtb为佐剂)分别免疫BALB/c小鼠后,进行尾蚴攻击感染实验。在攻击感染6wk后,剖杀小鼠计算各组的减虫率。　结果　各组的减虫率为rSj1433+福氏佐剂组32.20%,rSj1433+rSjGST+福氏佐剂组31.10%,rSj1433+Mtb佐剂组27.96%,rSj1433+rSjGST+Mtb佐剂组26.00%,rSjGST+Mtb佐剂组27.10%;各组的减卵率分别为(按以上组序)50.40%、53.30%、51.10%、58.60%和51.30%。　结论　rSj1433具有一定的抗血吸虫潜能,有可能成为抗日本血吸虫疫苗,但未见rSj1433和rSjGST的协同作用;Mtb激活扩增的γδT细胞在抗血吸虫免疫中的效果与福氏佐剂产生的免疫作用类似。     

rSj14-3-3和rSj14-3-3/SjGST对日本血吸虫虫卵肉芽肿形成的影响

目的　探讨日本血吸虫信号蛋白 14 - 3- 3基因重组蛋白 (rSj14 - 3- 3)及其与谷胱甘肽S转移酶融合蛋白(rSj14 - 3- 3/SjGST)对宿主肝虫卵肉芽肿形成的影响。 方法　用rSj14 - 3- 3和rSj14 - 3- 3/SjGST免疫雌性BALB/c小鼠 ,末次免疫后 5d ,各组小鼠均感染日本血吸虫尾蚴 4 0± 1条 /鼠 ,6周后 ,剖杀 ,取肝组织计数肝表面虫卵结节密度和肝切片上单个虫卵肉芽肿直径大小。结果　免疫组 (14 - 3- 3组和 14 - 3- 3/GST组 )和对照组肝表面虫卵结节数分别为 6 72±1 14、5 89± 1 0 3和 2 1 0 5± 1 2 6 ,前两者比后者分别减少了 6 8 0 8%和 72 0 2 % ;肝肉芽肿平均直径免疫组为 178 12±32 18μm和 14 8 13± 2 9 6 5 μm ,与对照组 2 75 0 0± 38 2 1μm相比分别减少了 35 2 3%和 4 6 13%。结论　重组抗原rSj14 - 3- 3和rSj14 - 3- 3/SjGST对日本血吸虫具有较好的抗病效果。     

14-3-3蛋白在心肌细胞缺氧预处理中的表达及意义

目的:研究14-3-3蛋白在心肌细胞缺氧预处理中的表达及意义。方法:实验用SD新生大鼠(1～3d龄),雌雄不拘,无菌取出乳鼠心脏,经分离附着组织,胰蛋白酶消化,纯化制成心肌细胞。在培养的第4天随机分为3组:正常对照组、缺氧/复氧(A/R)组、缺氧预处理(APC)组。各组分别进行以下指标观察:①心肌细胞搏动频率;②细胞存活率(MTT法);③培养液中乳酸脱氢酶(LDH)活性;④透射电镜观察细胞超微结构;⑤Western Blotting法检测14-3-3蛋白的表达变化。RT-PCR法检测14-3-3蛋白η、σmRNA的表达变化。结果:A/R组和APC组的14-3-3蛋白表达均上调,分别是正常对照组的(3.61±0.37)倍和(5.52±0.49)倍,A/R组和APC组与正常对照组比较、A/R组与APC组比较,均P<0.01。A/R组、APC组心肌细胞14-3-3η亚型mRNA分别为正常对照组的(1.82±0.30)倍、(2.93±0.52)倍,差异均有统计学意义(P<0.01);APC组与A/R组比较,差异亦有统计学意义(P<0.01)。A/R组、APC组心肌细胞14-3-3σ亚型mRNA表达量分别为正常对照组的...     

Association of 14-3-3 Proteins with Centrosomes

ABSTRACT: The 14-3-3 proteins are involved in diverse signal transduction pathways and interact physically with a wide variety of proteins. Here, we report the partial sequence analysis of a human spleen 14-3-3 protein, which was identified as a variant form of the ? isoform. A peptide antibody generated to the variant 14-3-3 localizes in the centrosome and spindle apparatus of mouse leukemic FDCP cells by immunofluorescence microscopy. Immunoblots of centrosomes isolated by sucrose density gradient centrifugation of cell lysates disclose only the ? and γ isoforms, while total cellular lysates contain the ?, γ, β and ζ isoforms of 14-3-3. These data suggest that a subset of total cellular 14-3-3 proteins are localized in the centrosomes and spindle apparatus. A differential localization of the centrosomal 14-3-3 was observed in mouse 3T3 cells. Serum-starved (quiescent) cells lack the centrosomal 14-3-3, but upon serum-stimulation of these quiescent cells, the centrosomal 14-3-3 reappears. We propose that a subset of intracellular 14-3-3 proteins are localized in the centrosome and spindle apparatus, and may in fact, link mitogenic signaling, the cell cycle, and perhaps the centrosome duplication cycle as well.     

日本血吸虫Sj14-3-3疫苗研究进展

日本血吸虫病是由日本血吸虫引起的一类严重危害人类健康的人兽共患寄生虫病,研制疫苗防治该病是目前的研究热点.Sj14-3-3蛋白是一种有效的疫苗分子,该文就Sj14-3-3蛋白疫苗和核酸疫苗的研究进展进行综述.     

肝癌组织中14-3-3基因差异表达的意义

目的:检测肝癌组织中,4-3-3基因家族成员表达差异的临床意义.方法:用TRIzol一步法提取肝癌组织、硬化肝组织及正常肝组织的总RNA并纯化mRNA.逆转录合成荧光分子(Cy3/Cy5)标记的cDNA探针与含有14-3-3基因家族成员的基因芯片杂交,用GenePix Pro3.0图像分析软件分析不同病变肝组织中该基因家族成员的表达差异,行半定量RT-PCR对结果进行验证并探讨差异表达基因的临床意义.结果:在肝癌组织中14-3-3基因家族成员呈差异表达,其中14-3-3γ在肝癌组织中明显下调,与肿瘤包膜的完整性相关.14-3-3η在肝癌组织中明显上调,与肿瘤患者的临床分期相关.14-3-3γ与14-3-3ηmRNA的表达强度呈负相关(γ=-0.403,P<0.05).结论:14-3-3基因家族调控机制的紊乱参与肝癌的发生、发展,其中14-3-3γ和14-3-3η与肝癌的关系最为密切.     

日本血吸虫重组信号蛋白14-3-3的纯化及抗体制备

目的制备日本血吸虫(中国大陆株)信号蛋白Sj14-3-3的多克隆抗体与单克隆抗体。方法将合Sj14-3-3重组蛋白的凝胶条带冻干磨粉,免疫家兔,制备抗Sj14-3-3多克隆抗血请;用电洗脱纯化的Sj14-3-3免疫BALB/c小鼠,用杂交瘤技术制备抗Sj14-3-3单克隆抗体。测定所得抗体效价及特异性鉴定。结果获得大量纯化的表达产物;制备的多克隆抗血清双扩效价达1:8～1:64。获得1株能稳定分泌抗Sj14-3-3单抗的杂交瘤细胞株4D9,单抗亚类为IgG1。此株单抗能与重组Sj14-3-3蛋白发生特异性反应。结论获得了高度敏感、特异的抗Sj14-3-3多克隆抗血清及稳定分泌抗Sj14-3-3单抗的杂交瘤细胞。     

多房棘球绦虫Em14-3-3抗原编码基因研究进展

本文介绍了多房棘球绦虫Em14-3-3蛋白，并对Em14-3-3抗原编码基因的研究进展进行了综述。     

日本血吸虫14-3-3抗原编码基因的扩增和克隆

目的克隆日本血吸虫14-3-3抗原的编码基因,以研究其用于血吸虫病免疫诊断和免疫预防效果.方法以日本血吸虫成虫RAN为模板逆转录合成cDNA链,设计合成引物,用PCR法扩增14-3-3抗原基因编码序列,将其克隆入pGEM-T载体,并用双酶切和以质粒为模板的PCR进行鉴定.结果RT-PCR扩增出一条约780bp大小的特异性条带,重组质粒的双酶切和以质粒为模板的PCR均获得了一条与RT-PCR扩增出大小相同带.结论日本血吸虫14-3-3抗原重组pGEM-T克隆载体的成功构建,为进一步的研究提供了条件.     

弓形虫信号转导蛋白14-3-3基因的克隆与表达

目的　体外扩增弓形虫RH株信号转导蛋白1433(Toxo1433)基因编码序列,构建原核表达质粒,并表达Toxo1433。　方法　收集、纯化弓形虫RH株速殖子,提取RNA,在设计合成的引物中引入EcoRI和XhoI酶切位点。应用RTPCR扩增Toxo1433基因片段,插入原核表达质粒pET28a中,重组子双酶切、PCR和测序鉴定,转化大肠杆菌BL21并以异丙基βD硫代半乳糖苷(IPTG)诱导表达。　结果　从弓形虫RH株RNA中扩增出803bp的Toxo1433基因片段,构建重组质粒pET28a/1433;IPTG诱导,SDSPAGE显示表达产物的大小约30.7kDa,Western印迹鉴定为Toxo1433。　结论　成功地从弓形虫RH株基因组DNA中获取了1433基因,构建了pET28a/Toxo1433重组质粒,并获得高效表达。     

日本血吸虫重组抗原rSj14-3-3免疫保护作用的初步研究

目的　初步探讨重组信号蛋白 14 3 3及 14 3 3与GST融合蛋白抗日本血吸虫尾蚴感染和抗血吸虫病的免疫保护作用。　方法　用rSj14 3 3和rSj14 3 3 /SjGST免疫BALB/c小鼠 ,日本血吸虫尾蚴经腹部皮肤攻击感染 ,收集实验组与对照组成虫和虫卵 ,计算减虫率和减卵率 ;间接ELISA法测定实验组与对照组小鼠免疫前、后血清中特异性IgG抗体水平的变化 ;显微镜下测量并比较实验组与对照组肝脏切片上单个虫卵肉芽肿大小 ,观察两种重组抗原对小鼠肝脏肉芽肿形成的影响。　结果　上述两种重组抗原在尾蚴攻击感染后的减虫率分别为 3 1.93 %和 3 4.3 9% ;每克肝组织减卵率分别为 5 3 .2 4%和 60 .0 6% ,每对成虫减卵率分别为 3 3 .3 9%和 40 .48% ;免疫前各组血清IgG抗体A值差异无显著性 ,免疫后实验组血清IgG抗体A值明显高于对照组 ;实验组小鼠肝脏虫卵肉芽肿平均直径比对照组分别下降3 5 .2 3 %和 46.13 %。　结论　信号蛋白 14 3 3在抗感染和抗病免疫中具有保护作用 ,复合多价疫苗的免疫保护作用可能优于单价疫苗。     

日本血吸虫信号传导蛋白14-3-3的制备及其特性分析

目的制备可溶性重组日本血吸虫信号传导蛋白14-3-3（rSj14-3-3）,并研究其免疫学特性。方法采用反转录聚合酶链反应方法从日本血吸虫成虫mRNA中制备Sj14-3-3基因cDNA片段,将此cDNA片段亚克隆至表达载体pGEX-4T-3的谷胱甘肽还原酶的基因下游,构建重组表达质粒Sj14-3-3/pGEX-4T-3。重组质粒转化大肠埃希菌BL21,转化子细菌采用异丙基-β-D-硫代吡喃半乳糖苷（IPTG）进行诱导,表达产物经SDS-PAGE以观察重组GST-Sj14-3-3表达情况。GST-rSj14-3-3经凝血酶消化后,经过Glutathione Sepharose-4B胶亲和层析制备纯化的rSj14-3-3。rSj14-3-3免疫家兔制备免疫兔血清,经免疫印迹试验分析rSj14-3-3免疫原性和反应性。结果日本血吸虫江苏株Sj14-3-3蛋白基因编码序列被成功克隆,开放阅读框的DNA序列与基因库中的登录序列同源性为99.08%。构建的含Sj14-3-3蛋白基因的重组表达质粒经IPTG诱导能表达分子量约为55 kDa的融合蛋白,融合蛋白经凝血酶切割和亲和层析获得纯化的rSj14-3-3。rSj14-3-3能诱导家兔产生高效价的特异性抗体,该抗体可识别重组和天然的14-3-3蛋白。结论本研究成功制备了可溶性rSj14-3-3,其具有良好的免疫原性与反应性。     

日本血吸虫14—3—3抗原编码基因的克隆及序列测定

为了寻找日本吸虫病新的诊断和候选疫苗分子,设计合成引物,以日本血吸虫成虫cDNA第一链为模板,用PCR法扩增出日本血吸虫14－3－3抗原（Sj14-3-3）基因编码序列,其大小约784bp,将其克隆入pGEM-T载体,重组质粒pGEM-T-Sj14-3-3经双酶切和以质粒为模板进行PCR扩增,均可获得一条与PCR产物一致的DNA片段,序列测定结果表明具有一个长度为765bp的完整开放阅读框,与曼氏血吸虫14－3－3核苷酸序列有高度同源性。本实验克隆了日本血吸虫14－3－3抗原的编码基因,并进行了序列测定,为进一步研究提供了条件。     

14-3-3 Proteins--a focus on cancer and human disease

14-3-3 Proteins are a ubiquitous family of molecules that participate in protein kinase signaling pathways within all eukaryotic cells. Functioning as phosphoserine/phosphothreonine-binding modules, 14-3-3 proteins participate in phosphorylation-dependent protein-protein interactions that control progression through the cell cycle, initiation and maintenance of DNA damage checkpoints, activation of MAP kinases, prevention of apoptosis, and coordination of integrin signaling and cytoskeletal dynamics. In this review, we discuss the regulation of 14-3-3 structure and ligand binding, with a focus on the role of 14-3-3 proteins in human disease, particularly cancer. We discuss the latest data on the role of different 14-3-3 isotypes, the interaction of 14-3-3 proteins with Raf, Cdc25, and various integrin family members, and the likelihood that 14-3-3 proteins could be useful therapeutic targets in the treatment of human disease.     

多房棘球绦虫重组BCG-Em14-3-3疫苗的构建及鉴定

目的 构建和鉴定多房棘球绦虫重组BCGEm14—3—3疫苗。方法 超声粉碎泡球蚴组织提取总RNA，通过RT—PCR扩增获得Em14—3-3的cDNA，将该基因定向克隆到大肠埃希菌-分枝杆菌穿梭表达载体pBCG的人结核分枝杆菌热休克蛋白（HSP）70启动子下游构建重组质粒pBCG—Em14-3—3，用电穿孔法将该质粒导入BCG构建多房棘球绦虫重组BCG-Em14—3—3疫苗。将该疫苗接种到含12μg／ml、HgCl2的罗氏培养基筛选培养3周。结果 重组pBCG—Em14—3-3质粒经酶切证实构建成功，rBCG—Em14-3-3疫苗能在含12μg／ml HgCl2的罗氏培养基上生长繁殖。结论 成功构建多房棘球绦虫重组BCGEm14-3-3疫苗，为泡球蚴病的防治提供了一种新方法。     

Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators

The particulate guanylyl cyclase A receptor (GC-A), via activation by its endogenous ligands atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP), possesses beneficial biological properties such as blood pressure regulation, natriuresis, suppression of adverse remodeling, inhibition of the renin-angiotensin-aldosterone system, and favorable metabolic actions through the generation of its second messenger cyclic guanosine monophosphate (cGMP). Thus, the GC-A represents an important molecular therapeutic target for cardiovascular disease and its associated risk factors. However, a small molecule that is orally bioavailable and directly targets the GC-A to potentiate cGMP has yet to be discovered. Here, we performed a cell-based high-throughput screening campaign of the NIH Molecular Libraries Small Molecule Repository, and we successfully identified small molecule GC-A positive allosteric modulator (PAM) scaffolds. Further medicinal chemistry structure–activity relationship efforts of the lead scaffold resulted in the development of a GC-A PAM, MCUF-651, which enhanced ANP-mediated cGMP generation in human cardiac, renal, and fat cells and inhibited cardiomyocyte hypertrophy in vitro. Further, binding analysis confirmed MCUF-651 binds to GC-A and selectively enhances the binding of ANP to GC-A. Moreover, MCUF-651 is orally bioavailable in mice and enhances the ability of endogenous ANP and BNP, found in the plasma of normal subjects and patients with hypertension or heart failure, to generate GC-A–mediated cGMP ex vivo. In this work, we report the discovery and development of an oral, small molecule GC-A PAM that holds great potential as a therapeutic for cardiovascular, renal, and metabolic diseases.

The global burden of cardiovascular diseases (CVDs) and its associated risk factors of hypertension, obesity, and renal dysfunction, all of which are major drivers for premature mortality, are rapidly growing worldwide (1, 2). While drug discovery continues in this area, there remains a high unmet need for novel therapies, especially with innovative molecular targets. Employing native and designer peptides, we and others have established the favorable pleiotropic properties of the particulate guanylyl cyclase A receptor (GC-A) through the generation of its second messenger 3′, 5′ cyclic guanosine monophosphate (cGMP) (3–6). In response to GC-A activation by the native cardiac hormones atrial natriuretic peptides (ANP) and b-type natriuretic peptides (BNP), such beneficial biological properties include the reduction in blood pressure (BP), natriuresis, suppression of adverse cardiorenal and CV remodeling, inhibition of the renin-angiotensin-aldosterone system (RAAS), and favorable metabolic properties (4–6). Most recently, studies from the PROVE-HF trial have reported that ANP is the predominant natriuretic peptide (NP) increased by sacubitril/valsartan (S/V) and is closely correlated with S/V mediated reverse remodeling, thus supporting a key role for GC-A activation in the actions of S/V (7). Taken together, these biological properties render the GC-A/cGMP pathway an unprecedented molecular target for CV therapeutics.Historically, GC-A therapeutics have been dependent on use of synthetic or recombinant peptides forms of ANP and BNP. Specifically, ANP and BNP are both approved for the treatment of acute heart failure (HF) via intravenous (IV) infusion in Japan and the United States, respectively (8, 9). Beyond the need for IV infusion, these ligands have short circulating half-lives due to their rapid enzymatic degradation by neprilysin (NEP) and receptor-mediated clearance through the NP clearance receptor, NPR-C (10). Thus, the development of designer NPs has evolved in an effort to overcome these therapeutic challenges related to short bioavailability and delivery. Indeed, MANP is a novel ANP analog that possesses greater resistance to NEP degradation compared to ANP and is in clinical trials for resistant hypertension (11, 12). However, as a peptide, MANP must be administered as an injection, similar to that of insulin in diabetes. Hence, the discovery of small molecules, which are noted for favorable oral bioavailability, would represent a major breakthrough in GC-A therapeutics.Allosteric ligands bind to sites on the receptor that are separate from the orthosteric binding site to which the endogenous ligands, such as ANP and BNP, bind (13). Positive allosteric modulators (PAMs) lack actions when binding to the receptor in the absence of the specific endogenous receptor ligand(s). As such, studies suggest that PAMs have high specificity to receptors (14). Furthermore, in animal models and humans, PAMs operate to physiological and pathophysiological variations in their endogenous ligand hormones and therefore are self-titrating to maximize cell signaling and avoid drug tolerance. To date, no such small molecules have been reported to target the GC-A receptor and to enhance its cGMP-mediated biological effects.The goal of the current study was to pursue a cell-based high-throughput screening (HTS) campaign to identify small molecule GC-A PAMs using the NIH Molecular Libraries Small Molecule Repository (MLSMR). Here, we report the discovery of small molecule GC-A PAM scaffolds and the identification of a lead molecule, MCUF-651. Moreover, we also designed the following studies to determine the ability of MCUF-651 to 1) augment cGMP in HEK293 cells overexpressing either GC-A or the alternative GC-B receptor so as to establish potency with the endogenous ligands for each receptor and selectivity for GC-A; 2) potentiate cGMP levels, in the presence of ANP, in primary cells naturally expressing GC-A including human renal proximal tubular cells (HRPTCs), human adipocytes (HAs), and human cardiomyocytes (HCM); 3) enhance ANP-mediated anti-hypertrophic actions in HCM; 4) assess the binding of MCUF-651 alone or in the presence of increasing concentrations of ANP/BNP or C-type natriuretic peptide (CNP) to human GC-A and GC-B, respectively; 5) determine the pharmacokinetics (PK) and oral bioavailability in mice; and 6) augment cGMP in a human plasma from normal subjects and patients with hypertension and HF using an ex vivo potency assay.     

Clinical implication of 14-3-3 epsilon expression in gastric cancer

AIM: To evaluate for the first time the protein and mRNA expression of 14-3-3ε in gastric carcinogenesis.METHODS: 14-3-3ε protein expression was determined by western blotting, and mRNA expression was examined by real-time quantitative RT-PCR in gastric tumors and their matched non-neoplastic gastric tissue samples.RESULTS: Authors observed a significant reduction of 14-3-3ε protein expression in gastric cancer (GC) samples compared to their matched non-neoplastic tissue. Reduced levels of 14-3-3ε were also associated with diffuse-type GC and early-onset of this pathology. Our data suggest that reduced 14-3-3ε may have a role in gastric carcinogenesis process.CONCLUSION: Our results reveal that the reduced 14-3-3ε expression in GC and investigation of 14-3-3ε interaction partners may help to elucidate the carcinogenesis process.     

Chemical screening identifies filastatin,a small molecule inhibitor of Candida albicans adhesion,morphogenesis, and pathogenesis

Infection by pathogenic fungi, such as Candida albicans, begins with adhesion to host cells or implanted medical devices followed by biofilm formation. By high-throughput phenotypic screening of small molecules, we identified compounds that inhibit adhesion of C. albicans to polystyrene. Our lead candidate compound also inhibits binding of C. albicans to cultured human epithelial cells, the yeast-to-hyphal morphological transition, induction of the hyphal-specific HWP1 promoter, biofilm formation on silicone elastomers, and pathogenesis in a nematode infection model as well as alters fungal morphology in a mouse mucosal infection assay. We term this compound filastatin based on its strong inhibition of filamentation, and we use chemical genetic experiments to show that it acts downstream of multiple signaling pathways. These studies show that high-throughput functional assays targeting fungal adhesion can provide chemical probes for study of multiple aspects of fungal pathogenesis.     

日本血吸虫(中国大陆株)信号蛋白14-3-3在原核细胞的高效融合表达和特性鉴定

目的　构建重组质粒pET2 8a -Sj14 - 3- 3,并在大肠杆菌中表达 ,检测表达产物的免疫活性。 方法　用亚克隆技术把Sj14 - 3- 3基因克隆至 pET2 8aT7启动子下游 ,转化大肠杆菌DH5α和BL2 1感受态细胞 ,经IPTG诱导表达 ,SDS -PAGE和Westernblot分析。结果　获得pET2 8a -Sj14 - 3- 3重组表达载体 ,SDS -PAGE和Westernblot显示Sj14 - 3- 3基因在 pET2 8a中表达的融合蛋白约为 32 4kDa ,与天然 14 - 3- 3蛋白具有相同的免疫活性。 结论　日本血吸虫信号蛋白14 - 3- 3在原核细胞中得以高效表达 ,表达产物具有免疫活性 ,为进一步研究其免疫保护作用和信号转导奠定了基础     

抗日本血吸虫重组信号蛋白14-3-3单克隆抗体的制备和鉴定

目的制备抗日本血吸虫重组信号蛋白14-3-3单克隆抗体,并鉴定抗体性质。方法以重组表达纯化的日本血吸虫信号蛋白14-3-3为抗原免疫BALB/c小鼠,采用杂交瘤技术制备单克隆抗体,采用酶联免疫吸附试验及免疫印迹法对获得的单克隆抗体进行类和亚类、效价、浓度、纯度、亲和常数、特异性和检测灵敏度的测定与鉴定。结果共获得6株针对日本血吸虫信号蛋白14-3-3的单克隆抗体,分别为5G9、3F1、3F7、5C6、5D1和1G6,抗体类型分别为IgG1、IgG1、IgG2a、IgG2b、IgG1和IgG1。对其中的单克隆抗体5G9分析显示,制备的腹水抗体效价为1∶1.28×105,亲和层析纯化后的浓度为5.3 mg/ml,纯度95%,亲和常数为5.1×107mol/L。免疫印迹试验结果表明,该单克隆抗体可与体外重组表达纯化的日本血吸虫14-3-3蛋白特异性结合,同时也能与日本血吸虫可溶性虫卵抗原、成虫排泄分泌抗原和成虫抗原特异性反应,而与大肠埃希菌、健康人血清和华支睾吸虫抗原均无明显交叉反应。HRP标记的单克隆抗体5G9检测14-3-3蛋白的灵敏度为31.25 ng/ml。结论本研究获得了6株能稳定分泌抗日本血吸虫14-3-3蛋白的单克隆抗体杂交瘤细胞株,为建立新的日本血吸虫活动性感染检测方法奠定了良好的基础。